Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04135846 · ClinicalTrials.gov registry record · Phase 2

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

A Phase 2 study of Alcohol Use Disorder (AUD), sponsored by Brown University.

Recruiting
Registry status
Phase 2
Development phase
184
Enrollment target
1
Study location

NCT04135846 is a Phase 2 study of Alcohol Use Disorder (AUD) that is actively recruiting participants, run by Brown University. The registered enrollment target is 184 participants, below the 1,818-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04135846, a Phase 2 study of Alcohol Use Disorder (AUD), is actively recruiting participants, sponsored by Brown University.

RECRUITING
Registry status
Phase 2
Development phase
184 participants
Enrollment target
1
Study location

Study Summary

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Doxazosin

Study Locations (1)

Rhode Island

  • Brown University - Providence

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2019-12-19
Est. Completion 2026-08-31
Phase Phase 2

Sponsor

Brown University

231 total trials

What the Registry Record Tells You About NCT04135846

The ClinicalTrials.gov registry entry for NCT04135846 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,818-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (90% lower). The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04135846 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT04135846 about?

NCT04135846 is a clinical study titled "Alpha-1 Blockade for Alcohol Use Disorder (AUD)". The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

What is the current status of trial NCT04135846?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2019-12-19. Estimated completion is 2026-08-31.

What conditions does trial NCT04135846 study?

This clinical trial studies the following conditions: Alcohol Use Disorder (AUD).

What interventions are being tested in trial NCT04135846?

The interventions under investigation include: Placebo (DRUG), Doxazosin (DRUG).

Who is sponsoring clinical trial NCT04135846?

This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04135846 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder (AUD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.